A Peek At What Celldex Therapeutics Inc. (CLDX) Insiders Are Doing

Celldex Therapeutics Inc. (NASDAQ:CLDX) saw an upside of 3.50% to close Friday at $55.88 after adding $1.89 on the day. The 5-day average trading volume is 377,500 shares of the company’s common stock. It has gained $56.85 in the past week and touched a new high 2 times within the past 5 days. An average of 506,025 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 557,388.

CLDX’s 1-month performance is 3.81% or $2.05 on its low of $50.61 reached on 09/20/21. The company’s shares have touched a 52-week low of $14.40 and high of $56.17, with the stock’s rally to the 52-week high happening on 10/01/21. YTD, CLDX has achieved 218.95% or $38.36 and has reached a new high 39 times. However, the current price is down -0.52%% from the 52-week high price.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

On Aug 10, 53 days have gone by since the last insider trading activity for Celldex Therapeutics Inc. (CLDX). Martin Samuel Bates (SVP and CFO) most recently sold 2,738 shares at $45.25 per share on Aug 10. This transaction cost the insider $123,894. Sr. VP & CCO, Wright Richard M., sold 20,832 shares at a price of $18.61 on Dec 14.

Valuation Metrics

Celldex Therapeutics Inc. (CLDX) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects. CLDX stock has a beta of 3.05. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 306.30 while the price-to-book (PB) in the most recent quarter is 12.15.

Celldex Therapeutics Inc.’s quick ratio for the period ended June 29 was 11.60, with the current ratio over the same period at 11.60 meaning that CLDX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00The trailing 12-month EBITDA margin is -641.30%. The firm’s gross profit as reported stood at $70.77 million against revenue of $7.42 million.

The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Celldex Therapeutics Inc.’s return on assets over the past 12 months stands at -28.90%. Return on investment over the past year is -29.70%, while its return on equity (ROE) trailing 12 months is -32.40%. In comparison, the average ROE for the broader industry over the past year is -36.91.

Earnings Surprise

For the quarterly period ending June 29 this year, Celldex Therapeutics Inc.’s cash and short-term investments amounted to $120.59 million against total debt of $2.78 million. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected CLDX to announce -$0.4 per share in earnings in its latest quarter, but it posted -$0.34, representing a 15.00% surprise. EBITDA for the quarter stood at more than -$12.8 million. CLDX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 22.27 million, with total debt at $2.78 million. Shareholders hold equity totaling $46.48 million

Technical Picture

Let’s look briefly at Celldex Therapeutics Inc. (CLDX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 60.86% to suggest the stock is trending Neutral, with historical volatility in this time period at 42.18%.

The stock’s 5-day moving average is $54.04, reflecting a +1.21% or $0.67 change from its current price. CLDX is currently trading +2.70% above its 20-day SMA, +108.74% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +26.05% and +217.50% respectively.

Stochastic %K and %D was 56.68% and 50.86% and the average true range (ATR) pointed at 2.39. The RSI (14) points at 60.65%, while the 14-day stochastic is at 84.46% with the period’s ATR at 2.34. The stock’s 9-day MACD Oscillator is pointing at -0.25 and 0.15 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Celldex Therapeutics Inc. (NASDAQ: CLDX), Jefferies launched coverage with a Buy rating. Analysts offering their rating for CLDX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CLDX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.

What is CLDX’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $60.00 and a high of $68.00, with their median price target at $66.00. Looking at these predictions, the average price target given by analysts is for Celldex Therapeutics Inc. (CLDX) stock is $64.83.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam